| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8820961 | Academic Radiology | 2018 | 7 Pages |
Abstract
This study showed that extrahepatic spread was a risk factor, and sorafenib treatment and superior BCLC stage were protective factors. Therefore, the study indicated that TACE combined with sorafenib was an effective and safe treatment for patients with BCLC stage B HCC without extrahepatic spread.
Related Topics
Health Sciences
Medicine and Dentistry
Radiology and Imaging
Authors
Jia-yan MM, Jian MD, Hong-liang MD, Yao-ting MD, Jiang-hong MM, Wei-dong MM, Dong MM, Xiong-ying MM, Lin-feng MD, PhD,